DNLI
Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.28
−2.28%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 43.13x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.26x
- Price / sales
- 988.18x
- Price / cash flow
- -8.21x
Enterprise value
- Enterprise value
- $2.9B
- EV / sales
- 798.68x
- EV / EBITDA
- -5.79x
- EV / EBIT
- -5.30x
- Market cap
- $3.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026